Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
PT

NASDAQ · PTCT

PTC Therapeutics, Inc.

Healthcare · Biotechnology

$59.97

Down-$4.49 (-6.97%)

Updated Nov 1, 2026, 7:46 PM

SID Score

4.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap
6.05B
P/E ratio
7.87
Dividend yield
0.00%
52-week range
$58.80 – $90.87
Volume
2.36M
Avg. volume
1.55M

Price performance · PTCT

PTCT price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

PTCT closed at $59.97 after 20 trading sessions, down 5.78% for the selected period.

Last close
$59.97
Period change
-5.78%
Period low
$59.24
Period high
$64.70
Daily close
View OHLC price history
PTCT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$64.75$65.34$59.64$59.972.36M
Oct 29, 2026$63.51$65.00$63.51$64.461.52M
Oct 28, 2026$61.82$63.11$61.00$63.02909.25K
Oct 27, 2026$61.07$62.31$59.87$62.091.12M
Oct 26, 2026$60.84$61.8499$60.46$61.07708.78K
Oct 23, 2026$62.30$63.49$59.965$60.59674.21K
Oct 22, 2026$62.62$63.49$62.24$63.04675.44K
Oct 21, 2026$63.14$63.74$62.41$62.62944.16K
Oct 20, 2026$62.27$63.235$61.5801$62.92965.77K
Oct 19, 2026$60.13$61.74$59.35$61.53943.99K
Oct 16, 2026$61.08$61.73$58.98$59.24788.98K
Oct 15, 2026$61.08$62.3099$59.88$60.991.05M
Oct 14, 2026$59.30$60.69$58.80$59.671.52M
Oct 13, 2026$62.64$62.75$59.82$59.921.05M
Oct 12, 2026$64.80$65.025$62.88$62.92745.21K
Oct 9, 2026$62.52$64.73$62.20$64.701.17M
Oct 8, 2026$62.66$62.86$61.65$62.561.23M
Oct 7, 2026$63.19$64.04$62.84$63.231.04M
Oct 6, 2026$64.53$65.27$62.92$63.701.26M
Oct 5, 2026$63.42$64.47$62.60$63.651.04M

Latest PTCT news

The latest Smart Investors Daily articles mentioning PTCT.

Stock researchCompany · Overview

PTCT research

Overview

Company profile and research snapshot.

Company profile

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$74.83
Implied upside
—
Analysts
—
PTCT recent ratings
DateFirmRatingTarget
Oct 30, 2026TD CowenBuy—
Oct 30, 2026Wells FargoOverweight—
Oct 30, 2026RBC CapitalSector Perform—
Oct 8, 2026RBC CapitalSector Perform—
Sep 22, 2026Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 31, 2026

PTC Therapeutics (PTCT) Stock Slides As Q3 Results Return To Loss

PTC Therapeutics just reported Q3 2026 and the headline is simple. Product revenue is now anchored by Sephience and Q3 brought in US$358 million of total revenue, yet the stock dropped about 7% on the day to roughly US$60. That is the sentiment shock. Coming into this report, the share price had already eased over the past month and the business remained loss making on a trailing basis. Today the market fixated on the earnings swing back to a quarterly loss, while the fundamentals that matter...

Yahoo · Oct 30, 2026

PTC Therapeutics (PTCT) Lifts Guidance As Fair Value Stays In Focus

PTC Therapeutics (PTCT) is back in focus after its third quarter, when revenue of US$357.81 million topped analyst forecasts and management lifted full year sales guidance for 2026. Despite the upbeat third quarter and higher 2026 revenue guidance, PTC Therapeutics’ share price has slipped, with a 1-month share price return of down 7.43% and a year to date share price return of down 21.85%. At the same time, the 3-year total shareholder return is up about 3x and the 5-year total shareholder...

Yahoo · Oct 30, 2026

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of 9.620 shares of its common stock and 11,535 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 13 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By